Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerages
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn
Bicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
Bicycle (BCYC) Q2 Revenue Falls 69%
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals